Vikingquest wrote:"liberation treatment is vastly superior to HSCT in producing a beneficial result to MS patients"
I assume that this is a joke?
Step away from the CCSVI Cool-Aid, and do not drink it anymore. Normal cognitive function will resume after it leaves your system.
Have you even read the figures for HSCT?
I have. They tell me that in one of the earlier studies 40% of the participants died. That's no laughing matter. While some might characterize this as reckless disregard for the lives of MS patients, perhaps others might characterize it as commitment to the autoimmune model of MS. Though researchers have since vastly improved their fatality rates, radical chemotherapy nevertheless represents a rather extreme form of treatment.
The results seem to me to be mixed. In any case, there have been no large scale randomized treatment trials. In that respect, it's no further ahead than angioplasty. The latest I can find is from 2009 in this study
Between January, 2003, and February, 2005, 21 patients were treated. Engraftment of white blood cells and platelets was on median day 9 (range day 8–11) and patients were discharged from hospital on mean day 11 (range day 8–13). One patient had diarrhoea due to Clostridium difficile and two patients had dermatomal zoster. Two of the 17 patients receiving alemtuzumab developed late immune thrombocytopenic purpura that remitted with standard therapy. 17 of 21 patients (81%) improved by at least 1 point on the Kurtzke expanded disability status scale (EDSS), and five patients (24%) relapsed but achieved remission after further immunosuppression. After a mean of 37 months (range 24–48 months), all patients were free from progression (no deterioration in EDSS score), and 16 were free of relapses. Significant improvements were noted in neurological disability, as determined by EDSS score (p<0·0001), neurological rating scale score (p=0·0001), paced auditory serial addition test (p=0·014), 25-foot walk (p<0·0001), and quality of life, as measured with the short form-36 (SF-36) questionnaire (p<0·0001).
This can be stacked up against Zamboni's results:
Outpatient endovascular treatment of CCSVI was feasible, with a minor and negligible complication rate. Postoperative venous pressure was significantly lower in the IJVs and AZY (P < .001). The risk of restenosis was higher in the IJVs compared with the AZY (patency rate: IJV, 53%; AZY, 96%; odds ratio, 16; 95% confidence interval, 3.5-72.5; P < .0001). CCSVI endovascular treatment significantly improved MS clinical outcome measures, especially in the RR group: the rate of relapse-free patients changed from 27% to 50% postoperatively (P < .001) and of MR Gad+ lesions from 50% to 12% (P < .0001). The Multiple Sclerosis Functional Composite at 1 year improved significantly in RR patients (P < .008) but not in PP or SP. Physical QOL improved significantly in RR (P < .01) and in PP patients (P < .03), with a positive trend in SP (P < .08). Mental QOL showed significant improvement in RR (P < .003) and in PP (P < .01), but not in SP.
Don't get me wrong. I admire and respect patients who have braved HSCT. They are heroes in my books. And, indeed, HSCT has produced some initial impressive results. I happen to think that an autoimmune defect might be part of the bigger picture along with impaired blood flow.
But Zamboni's results are equally impressive using a relatively simple procedure with a low complication rate. No way would I consider playing Russian Roulette with my immune system with HSCT. Meanwhile, liberation treatment has brought me amazing results in my decades long heretofore losing battle against MS.
So yeah ....pass me some more of that Kool Aide Dr. Zamboni.